Activation markers in Behcet disease;Behçet hastaliǧinda aktivite belirteçleri

Turkderm Deri Hastaliklari ve Frengi Arsivi

Volumn 43, Issue SUPPL. 2, 2009, Pages 74-86

  Türsen, Ümit ^a  

^a MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Activity; Behcet disease; Markers

Indexed keywords

ABDOMINAL PAIN; ANAMNESIS; ARTHRALGIA; ARTHRITIS; BEHCET DISEASE; BEHCET DISEASE CURRENT ACTIVITY FORM; BLOODY DIARRHEA; CLINICAL FEATURE; DISEASE ACTIVITY; ERYTHEMA NODOSUM; FATIGUE; GENITAL ULCER; HEADACHE; HUMAN; INSTRUMENT VALIDATION; MOUTH ULCER; NAUSEA; PHYSICAL EXAMINATION; REVIEW; SUPERFICIAL THROMBOPHLEBITIS; VOMITING;

EID: 79551494845     PISSN: 1019214X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (172)

1. Pay S, Abbasov T, Erdem H, Musabak U, Simsek I, Pekel A, Akdogan A, Sengul A, Dinc A. Serum MMP-2 and MMP-9 in patients with Behçet's disease: do their higher levels correlate to vasculo-Behçet's disease associated with aneurysm formation? Clin Exp Rheumatol 2007;25:70-5.
2. Kwon SR, Lim MJ, Park. SG, Moon YS, Park W. Decreased protein S activity is related to the disease activity of Behcet's disease. Rheumatol Int 2006;27:39-43.
3. Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement. Int J Dermatol 2009;48:259-64.
4. Evereklioglu C. Current Concepts in the Etiology and Treatment of Behcet Disease. Surv Ophthalmol 2005; 50:297-350. (Pubitemid 40828225)
5. Müftüoǧlu AU, Yazici H, Yurdakul S, Tüzün Y, Pazarli H, Güngen G, Deniz S. Behçet's disease. Relation of serum C-reactive protein and erythrocyte sedimentation rates to disease activity. Int J Dermatol 1986;25:235-9.
6. Bang D, Kim HS, Lee ES, Lee S. The significance of laboratory tests in evaluating the clinical activity of Behçet's disease. In: Behçet' s disease. Eds. Bang D, Lee ES, Lee S. International conference on Behçet's disease. 9th: Seoul, Korea, 2000: 125-7.
7. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behçet's disease: evaluation of a new instrument to measure clinical activity. Rheumatol 1999;38:728-33. (Pubitemid 29507389)
8. Köse O, Arca E, Akgül O, Erbil K. The levels of serum neopterin in Behçet's disease - objective mark.er of disease activity. J Dermatol Sci 2006;42:128-30. (Pubitemid 44316798)
9. Aygündüz M, Bavbek N, Oztürk M, Kaftan O, Koşar A, Kirazli S. Serum beta 2-microglobulin reflects disease activity in Behçet's disease. Rheumatol Int 2002;22:5-8.
10. Taysi S, Demircan B, Akdeniz N, Atasoy M, Sari RA. Oxidant/antioxidant status in men with Behçet's disease. Clin Rheumatol 2007;26:418-22.
11. Erkiliç K, Evereklioglu C, Cekmen M, Ozkiris A, Duygulu F, Dogan H. Adenosine deaminase enzyme activity is increased and negatively correlates with catalase, superoxide dismutase and glutathione peroxidase in patients with Behçet's disease: original contributions/clinical and laboratory investigations. Mediators Inflamm 2003;12:107-16. (Pubitemid 36783250)
12. Sunakawa M, Ohshio G. Serum secretory IgA levels in patients with Behçet disease. Metab Pediatr Syst Ophthalmol 1989;12:110-2.
13. Scully C, Boyle P, Yap PL. Immunoglobulins G, M, A, D and E in Behcet's syndrome. Clin Chim Acta 1982;120:237-42.
14. Adinolfi M, Lehner T. C9 and factor B as acute phase proteins and their diagnostic and prognostic value in disease. Exp Clin Immunogenet 1988;5:123-32.
15. Rumfeld WR, Morgan BP, Campbell AK. The ninth complement component in rheumatoid arthritis, Behçet's disease and other rheumatic diseases. Br J Rheumatol 1986;25:266-70.
16. Kure T, Kogure M. Complement regulatory proteins CR 1, MCP, DAF, and MACIF levels in patients with Behçet's disease. Nippon Ganka Gakkai Zasshi 1996;100:376-80.
17. Hamza M, Ayed K, Euch M, Moalla M, Ben Ayed H. Synovial fluid complement levels in Behçet's disease Ann Rheum Dis 1984;43:767.
18. Taylor PV, Chamberlain MA, Scott JS. Autoreactivity in patients with Behçet's disease. Br J Rheumatol 1993;32:908-10.
19. Vaiopoulos G, Hatzinikolaou P, Tsiroyanni A, Mavropoulos S, Stamatelos G, Terzoglou K, Tzonou A, Economidou I, Kaklamanis P. Anti-neutrophil cytoplasmic antibodies in Adamantiadis-Behçet's disease. Br J Rheumatol 1994;33:406-7.
20. Pereira RM, Gonçalves CR, Bueno C, Meirelles Ede S, Cossermelli W, de Oliveira RM. Anticardiolipin antibodies in Behçet's syndrome: a predictor of a more severe disease. Clin Rheumatol 1989;8:289-91.
21. Uchio E, Stanford M, Hasan A, Satoh S, Ohno S, Shinnick T, van der Zee R, Mizushima Y, Lehner T. HSP-derived peptides inducing uveitis and IgG and IgA antibodies. Exp Eye Res 1998;67:719-27.
22. Taşçi B, Direskeneli H, Serdaroglu P, Akman G, Eraksoy M, Direskeneli SG. Humoral immune response to mycobacterial heat shock protein (hsp) 65 in the cerebrospinal fluid of neuro-Behçet patients. Clin Exp Immunol 1998;113:100-4.
23. Souza RC, Lage L, Goldesntein-Schainberg C, Macedo AR, Carrasco S, Gonçalves CR. Anti-endothelial cell antibodies and central nervous system involvement in Behçet's disease. Clinics (Sao Paulo) 2007;62:685-90.
24. Freysdottir J, Lau S, Fortune F. Gammadelta T cells in Behçet's disease (BD) and recurrent aphthous stomatitis (RAS). Clin Exp Immunol 1999;118: 451-7.
25. Ahn JK, Chung H, Lee DS, Yu YS, Yu HG. CD8brightCD56+ T cells are cytotoxic effectors in patients with active Behcet's uveitis. J Immunol 2005;175:6133-42.
26. Valesini G, Pivetti-Pezzi P, Mastrandrea F, Moncada A, Cuomo M, Natali PG. Clin Evaluation of T cell subsets in Behçet's syndrome using anti-T cell monoclonal antibodies. Exp Immunol 1985;60:55-60.
27. Freysdottir J, Hussain L, Farmer I, Lau SH, Fortune F. Diversity of gammadelta T cells in patients with Behcet's disease is indicative of polyclonal activation. Oral Dis 2006;12:271-7.
28. Direskeneli H, Eksioglu-Demiralp E, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Oligoclonal T cell expansions in patients with Behçet's disease. Clin Exp Immunol 1999;117:166-70. (Pubitemid 29292793)
29. Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999;42:1967-74.
30. Ates A, Aydintug O, Olmez U, Tokgoz G, Gurler A. Cellular DNA content of lymphocytes in Behçet's disease (BD). In: Behçet' s disease. Eds. Bang D, Lee ES, Lee S. 9th International conference on Behçet's disease, Seoul, Korea, 2000: 187-90.
31. Eksioglu-Demiralp E, Direskeneli H, Ergun T, Fresko I, Akoglu T. Increased CD4+CD16+ and CD4+CD56+ T cell subsets in Behçet's disease. Rheumatol Int 1999;19:23-6.
32. Ekşioglu-Demiralp E, Kibaroglu A, Direskeneli H, Yavuz S, Karsli F, Yurdakul S, Yazici H, Akoglu T. Phenotypic characteristics of B cells in Behçet's disease: increased activity in B cell subsets. J Rheumatol 1999;26:826-32. (Pubitemid 29195669)
33. Sahin S, Lawrence R, Direskeneli H, Hamuryudan V, Yazici H, Akoǧlu T. Monocyte activity in Behçet's disease. Br J Rheumatol 1996;35:424-9.
34. Olmez U, Keskin G, Duzgun N, Tutkak H, Tokgoz G, Gurler A. Serum soluble CD23 levels in the patients with Behçet's diasease. In: Behcet's disease. Ed Hamza M. 7th International Conference on Behçet's disease. Tunus 1997: 54-6.
35. Martínez M, Ricart JM, Ruiz-Aja S, Rus A, Todolí J, Calvo J, Vayá A. Platelet activation and red blood cell phosphatidylserine exposure evaluated by flow cytometry in patients with Behçet's disease: are they related to thrombotic events. Pathophysiol Haemost Thromb 2007;36:18-22.
36. Navarro S, Ricart JM, Medina P, Vayá A, Villa P, Todolí J, Estellés A, Micó ML, Aznar J, España F. Activated protein C levels in Behçet's disease and risk of venous thrombosis. Br J Haematol 2004;126:550-6.
37. Ureten K, Ertenli I, Oztürk MA, Kiraz S, Onat AM, Tuncer M, Okur H, Akdogan A, Apras S, Calgüneri M. Neutrophil CD64 expression in Behçet's disease. J Rheumatol 2005;32:849-52. (Pubitemid 40676494)
38. Düzgün N, Ayaslioglu E, Tutkak H. Serum soluble CD30 levels in Behçet's disease. Clin Exp Rheumatol 2004;22:17-20.
39. Kahan A, Hamzaoui K, Ayed K. Abnormalities of T lymphocyte subsets in Behçet's disease demonstrated with anti-CD45RA and anti-CD29 monoclonal antibodies. J Rheumatol 1992;19:742-6.
40. Onder M, Kokturk N, Poyraz A, Oztas MO. Expression of CCR5 in Behçet's disease. Adv Exp Med Biol 2003;528:245-7.
41. Kurokawa MS, Suzuki N. Behcet's disease. Clin Exp Med 2004;3:10-20.
42. Evereklioglu C, Er H, Türköz Y, Cekmen M. Serum levels of TNFalpha, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behçet's disease. Mediators Inflamm 2002;11:87-93. (Pubitemid 34526411)
43. Akman-Demir G, Tüzün E, Içöz S, Yeşilot N, Yentür SP, Kürtüncü M, Mutlu M, Saruhan-Direskeneli G. Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome. Cytokine 2008;44:373-6.
44. Gür-Toy G, Lenk N, Yalcin B, Aksaray S, Alli N. Serum interleukin-8 as a serologic mark.er of activity in Behçet's disease. Int J Dermatol 2005;44:657-60.
45. Durmazlar SP, Ulkar GB, Eskioglu F, Tatlican S, Mert A, Akgul A. Significance of serum interleukin-8 levels in patients with Behcet's disease: high levels may indicate vascular involvement. Int J Dermatol 2009;48:259-64.
46. Bardak Y, Aridoǧan BC. The demonstration of serum interleukin 6-8, tumor necrosis factor-alpha, complement, and immunoglobulin levels in Behçet's disease with ocular involvement. Ocul Immunol Inflamm 2004;12:53-8.
47. Zouboulis CC, Katsantonis J, Ketteler R, Treudler R, Kaklamani E, Hornemann S, Kaklamanis P, Orfanos CE. Adamantiades-Behçet's disease: interleukin-8 is increased in serum of patients with active oral and neurological manifestations and is secreted by small vessel endothelial cells. Arch Dermatol Res 2000;292:279-84. (Pubitemid 30386437)
48. Frassanito MA, Dammacco R, Cafforio P, Dammacco F. Th1 polarization of the immune response in Behçet's disease: a putative pathogenetic role of interleukin-12. Arthritis Rheum 1999; 42:1967-74.
49. Aridogan BC, Yildirim M, Baysal V, Inaloz HS, Baz K, Kaya S. Serum Levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behçet's disease. J Dermatol 2003;30:602-7.
50. Erdem F, Güdoǧdu M, Kiki I, Ali Sari R, Kiziltunç A. Vascular endothelial and basic fibroblast growth factor serum levels in patients with Behçet's disease. Rheumatol Int 2005;25:599-603. (Pubitemid 41414057)
51. Ertenli I, Kiraz S, Calguneri M, Celik I, Erman M, Haznedaroglu IC, Kirazli S. Synovial fluid cytokine levels in Behcet's disease. Clin Exp Rheumatol 2001;19 Suppl 24:37-41.
52. Aki T, Karincaoglu Y, Seyhan M, Batcioglu K. Serum substance P and calcitonin gene-related peptide levels in Behçet's disease and their association with disease activity. Clin Exp Dermatol 2006;31:583-7.
53. Ben Ahmed M, Houman H, Miled M, Miled M, Dellagi K, Louzir H. Involvement of chemokines and Th1 cytokines in the pathogenesis of mucocutaneous lesions of Behçet's disease. Arthritis Rheum 2004;50:2291-5. (Pubitemid 38924408)
54. Kulaber A, Tutkun TI, Yentür SP, Akman DG, Kaneko F, Gül A, Direskeneli SG. Pro-inflammatory cellular immune response in Behçet's disease Rheumatol Int 2007;27:1113.
55. Katsantonis J, Adler Y, Orfanos CE, Zouboulis CC. Adamantiades- Behçet's disease: serum IL-8 is a more reliable mark.er for disease activity than C-reactive protein and erythrocyte sedimentation rate. Dermatology 2000;201:37-9.
56. Ben Ahmed M, Houman H, Ben Ghorbel I, Braham-Sfaxi A, Miled M, Dellagi K, Louzir H. Cytokine expression within mucocutaneous lesions of Behçet's disease: involvement of proinflammatory and Th1 cytokines. Adv Exp Med Biol 2003; 528:343-6.
57. Kötter I, Koch S, Vonthein R, Rückwaldt U, Amberger M, Günaydin I, Zierhut M, Stübiger N. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature. Clin Exp Rheumatol 2005;23:20-6.
58. Kosar A, Haznedaroglu S, Karaaslan Y, Büyüasik Y, Haznedaroglu IC, Ozath D, Sayinalp N, Ozcebe O, Kirazli S, Dündar S. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease. Rheumatol Int 1999;19:11-4.
59. Direskeneli H, Ergun T, Yavuz S, Hamuryudan V, Demiralp EE. Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease Clin Rheumatol. 2008;27:373-5.
60. Sari RA, Kiziltunç A, Taysi S, Akdemir S, Gündoǧdu M. Levels of soluble E-selectin in patients with active Behcet's disease. Clin Rheumatol 2005;24:55-9.
61. Ateş A, Tiryaki OA, Olmez U, Tutkak H. Serum-soluble selectin levels in patients with Behçet's disease. Clin Rheumatol 2007;26:411-7. (Pubitemid 46486975)
62. Assaad-Khalil SH, Abou-Seif M, Youssef I, Farahat N. L-selectin expression on leukocytes of patients with Behçet's disease. Adv Exp Med Biol 2003;528:273-8.
63. Haznedaroglu E, Karaaslan Y, Büyükaşik Y, Koşar A, Ozcebe O, Haznedaroglu C, Kirazli E, Dündar SV. Selectin adhesion molecules in Behçet's disease. Ann Rheum Dis 2000;59:61-3.
64. Uchio E, Matsumoto T, Tanaka SI, Ohno S. Soluble intercellular adhesion molecule-1 (ICAM-1), CD4, CD8 and interleukin-2 receptor in patients with Behçet's disease and Vogt-Koyanagi-Harada's disease. Clin Exp Rheumatol 1999;17:179-84.
65. Ateş A, Aydintuǧ O, Olmez U, Düzgün N, Duman M. Serum homocysteine level is higher in Behçet's disease with vascular involvement. Rheumatol Int 2005;25:42-4.
66. Er H, Evereklioglu C, Cumurcu T, Türköz Y, Ozerol E, Sahin K, Doganay S. Serum homocysteine level is increased and correlated with endothelin-1 and nitric oxide in Behçet's disease. Br J Ophthalmol 2002;86:653-7.
67. Oztürk MA, Ertenli I, Kiraz S, Haznedaroǧlu CI, Celik I, Kirazli S, Calgüneri M. Plasminogen activator inhibitor-1 as a link between pathological fibrinolysis and arthritis of Behçet's disease. Rheumatol Int 2004;24:98-102. (Pubitemid 38388752)
68. Ozoran K, Düzgün N, Gürler A, Tutkak H, Tokgöz G. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behçet's disease. Scand J Rheumatol 1995;24:376-82.
69. Düzgün N, Ayaşlioǧlu E, Tutkak H, Sahin M, Aydintuǧ O, Olmez U. Plasma thrombomodulin levels in patients with Behçet's disease. Rheumatol Int 2003;23:130-3. (Pubitemid 36712989)
70. Haznedaroglu IC, Ozcebe OI, Ozdemir O, Celik I, Dündar SV, Kirazli S. Impaired haemostatic kinetics and endothelial function in Behçet's disease. J Intern Med 1996;240:181-7. (Pubitemid 26356039)
71. Yapişlar H, Aydogan S, Borlu M, Ascioglu O. Decreased nitric oxide and increased platelet aggregation levels in patients with Behçet's disease. Thromb Res 2007;119:461-5. (Pubitemid 46149885)
72. Yurdakul S, Hekim N, Soysal T, Fresko I, Bavunoglu I, Ozbakir F, Tabak F, Melikoglu M, Hamuryudan V, Yazici H. Fibrinolytic activity and d-dimer levels in Behçet's syndrome. Clin Exp Rheumatol 2005;23:53-8.
73. Mineshita S, Wang LM, Miura A, Umezu S, Honda Y, Satoh T. The influence of plasma fibrinogen and serum ferrum on blood viscosity in Adamantiades- Behçet's disease. Adv Exp Med Biol 2003;528:405-12.
74. Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Behçet's disease. Am J Ophthalmol 2004;137:850-7. (Pubitemid 38582037)
75. Yalçindaǧ FN, Batioǧlu F, Ozdemir O, Cansizoǧlu E, Eǧin Y, Akar N. Soluble endothelial protein C receptor levels in Behçet patients with and without ocular involvement. Graefes Arch Clin Exp Ophthalmol 2008;246:1603-8.
76. Beyan E, Sadikoǧlu B, Ertuǧrul E, Beyan C. Von Willebrand factor antigen levels in Behçet disease. Am J Hematol 2005;79:70-2.
77. Akarsu M, Demirkan F, Ozsan GH, Onen F, Yüksel F, Ozkan S, Undar B.. Increased levels of tissue factor pathway inhibitor may reflect disease activity and play a role in thrombotic tendency in Behçet's disease. Am J Hematol 2001;68:225-30. (Pubitemid 33108424)
78. Esmat S, El Sherif H, Anwar S, Fahmy I, Elmenyawi M, Shaker O. Lipoprotein (a) and nitrites in Behcet's disease: relationship with disease activity and vascular complications. Eur J Dermatol 2006;16:67-71. (Pubitemid 43219409)
79. Tatlican S, Gülbahar Ö, Şimşek KK, Eren C, Durmazlar PK, Eskioǧlu F. Behçet Hastalarinda Serum Resistin Düzeyleri ve Hastalik Aktivitesi ile İlişkisi Serum Resistin Levels in Behcet's Disease Patients and Correlation with Disease Activity. TURKDERM 2009;43-3:100-3.
80. Lehner T, Adinolfi M. Acute phase proteins, C9, factor B, and lysozyme in recurrent oral ulceration and Behçet's syndrome. J Clin Pathol 1980;33:269-75.
81. Inanc N, Mumcu G, Birtas E, Elbir Y, Yavuz S, Ergun T, Fresko I, Direskeneli H. Serum mannose-binding lectin levels are decreased in Behcet's disease and associated with disease severity. J Rheumatol 2005;32:287-91. (Pubitemid 40209127)
82. Inanc N, Birtas E, Yavuz S, Ergun T, Direskeneli H. Low serum mannose- binding lectin levels in Behçet's disease. Adv Exp Med Biol 2003;528:287-9.
83. Kirino Y, Takeno M, Watanabe R, Murakami S, Kobayashi M, Ideguchi H, Ihata A, Ohno S, Ueda A, Mizuki N, Ishigatsubo Y. Association of reduced heme oxygenase-1 with excessive Toll-like receptor 4 expression in peripheral blood mononuclear cells in Behçet's disease. Arthritis Res Ther 2008;10:R16. (Pubitemid 351280041)
84. Oztaş P, Lortlar N, Polat M, Alli N, Omeroǧlu S, Basman A. Caspase- 9 expression is increased in endothelial cells of active Behçet's disease patients. Int J Dermatol 2007;46:172-6. (Pubitemid 46671694)
85. Li B, Yang P, Zhou H, Zhang Z, Xie C, Lin X, Huang X, Kijlstra A. T-bet expression is upregulated in active Behçet's disease. Br J Ophthalmol 2003;87:1264-7. (Pubitemid 37193919)
86. Kitaichi N, Kotake S, Sasamoto Y, Namba K, Matsuda A, Ogasawara K, Onoé K, Matsuda H, Nishihira J. Prominent increase of macrophage migration inhibitory factor in the sera of patients with uveitis. Invest Ophthalmol Vis Sci 1999;40:247-50. (Pubitemid 29029596)
87. Niino M, Ogata A, Kikuchi S, Tashiro K, Nishihira J. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behçet's disease. J Neurol Sci 2000;179:127-31.
88. Erel A, Ozsoy E, Biberoǧlu G, Bilgihan A, Hasanoǧlu A, Yis MO, Atahan C, Oruk S. Serum levels of vitamins A, C, and E, beta-carotene, selenium, and zinc in patients with Behçet's disease: a controlled study. Biol Trace Elem Res 2003;95:97-106.
89. Saglam K, Serce AF, Yilmaz MI, Bulucu F, Aydin A, Akay C, Sayal A. Trace elements and antioxidant enzymes in Behçet's disease. Rheumatol Int 2002;22:93-6. (Pubitemid 34993515)
90. Delilbaşi E, Turan B, Yücel E, Saşmaz R, Işimer A, Sayal A. Selenium and Behçet's disease. Biol Trace Elem Res 1991;28:21-5.
91. Cengiz K, Gürkaynak F. Serum zinc, copper and magnesium in Behçet's disease. Mater Med Pol 1988;20:190-3.
92. Mirza GE, Karaküçük S, Er M, Güngörmü ş N, Karaküçük I, Saraymen R. Tear nitrite and nitrate levels as nitric oxide end products in patients with Behçet's disease and non-Behçet's uveitis. Ophthalmic Res 2001;33:48-51.
93. Calis M, Ates F, Yazici C, Kose K, Kirnap M, Demir M, Borlu M, Evereklioglu C. Adenosine deaminase enzyme levels, their relation with disease activity, and the effect of colchicine on adenosine deaminase levels in patients with Behçet's disease. Rheumatol Int 2005;25:452-6.
94. Aoyama-Hayashi E, Matsuda T, Ohya N, Tanaka C, Kongozi M, Kamo C, Hotta M, Ikejima H, Shiraishi M, Mizushima Y. Soluble Fas ligand levels in cerebrospinal fluid in neuro-Behçet's disease. Adv Exp Med Biol 2003;528:389-91.
95. Kim WU, Chung SM, Han TW, Sah WJ, Kim MH. Elevated soluble Fas in aqueous humor of patients with Behcet's uveitis: correlation with uveitis severity. Jpn J Ophthalmol 2002;46:18-23.
96. Takeuchi A, Haraoka H, Hashimoto T. Increased serum alkaline phosphatase activity in Behçet's disease. Clin Exp Rheumatol 1989;7:619-21. (Pubitemid 20100987)
97. Accorinti M, Bruscolini A, Lambiase A, Speranza S, Bonini S, Pivetti- Pezzi P. Nerve growth factor in Behçet's disease. Adv Exp Med Biol 2003;528:283-5.
98. Jockers-Scherübl MC, Zouboulis CC, Boegner F, Hellweg R. Is nerve growth factor a serum mark.er for neurological and psychiatric complications in Behcet's disease? Lancet 1996;347:982.
99. Shahram F, Davatchi F, Nadji A, Jamshidi A, Akbarian M, Gharibdoost F, Chams C. Urine abnormalities in Behçet's disease. Study of 4704 cases. Adv Exp Med Biol 2003;528:477-8.
100. Kaya TI, Dur H, Tursen U, Gurler A. Association of class I HLA antigens with the clinical manifestations of Turkish patients with Behçet's disease. Clin Exp Dermatol 2002;27:498-501.
101. Shahram F, Davatchi F, Nadji A, Jamshidi A, Bahar K, Akbarian M, Gharibdoost F. Association of HLA-B51 with clinical expression of Behçet's disease. Analysis of 201 Iranian patients. Adv Exp Med Biol 2003;528:147-8.
102. Zouboulis CC, Vaiopoulos G, Marcomichelakis N, Palimeris G, Markidou I, Thouas B, Kaklamanis P. Onset signs, clinical course, prognosis, treatment and outcome of adult patients with Adamantiades- Behçet's disease in Greece. Clin Exp Rheumatol 2003;21:19-26.
103. Tamer L, Tursen U, Eskandari G, Ates NA, Ercan B, Yildirim H, Atik U. N-acetyltransferase 2 polymorphisms in patients with Behcet's disease. Clin. Exp. Dermatol 2005;30:56-60.
104. Tursen U, Tamer L, Eskandari G, Kaya TI, Ates NA, Ikizoglu G, Atik U. Glutathione S-transferase polymorphisms in patients with Behcet's disease. Arch Dermatol Res 2004;296:185-7. (Pubitemid 39371414)
105. Tursen U, Tamer L, Api H, Yildirim H, Baz K, Ikizoglu G, Atik U. Cytochrome P450 polymorphisms in patients with Behcet's disease. Int J Dermatol 2007;46:153-6.
106. Tursen U, Kaya TI, Eskandari G, Gunduz O, Yazar M, Ikizoglu G, Atik U. Association of factor V Leiden and prothrombin gene mutation with Behcet's disease. Arch Dermatol Res 2001;293:537-9.
107. Polat G, Eskandari G, Kaya TI, Tursen U, Bagdatoglu O, Ikizoglu G, Atik U. Association of the platelet glycoprotein Ia C807T/G873A gene polymorphism and thrombosis in Behcet patients. Haematologia (Budap) 2002;32:121-8. (Pubitemid 36002098)
108. Davies PG, Fordham JN, Kirwan JR, Barnes CG, Dinning WJ. The pathergy test and Behçet's syndrome in Britain. Ann Rheum Dis 1984;43:70-3.
109. Krause I, Molad Y, Mitrani M, Weinberger A. Pathergy reaction in Behçet's disease: lack of correlation with mucocutaneous manifestations and systemic disease expression. Clin Exp Rheumatol 2000;18:71-4.
110. Koç Y, Güllü I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci F, Akkaya S. Vascular involvement in Behçet's disease. J Rheumatol 1992;19:402-10.
111. Yazici H, Tüzün Y, Tanman AB, Yurdakul S, Serdaroglu S, Pazarli H, Müftüoglu A. Male patients with Behçet's syndrome have stronger pathergy reactions. Clin Exp Rheumatol 1985;3:137-41.
112. Yurdakul S, Güaydin I, Tüzün Y, Tankurt N, Pazarli H, Ozyazgan Y, Yazici H. The prevalence of Behçet's syndrome in a rural area in northern Turkey. J Rheumatol 1988;15:820-2.
113. Chang HK, Cheon KS. The clinical significance of a pathergy reaction in patients with Behcet's disease. J Korean Med Sci 2002;17:371-4.
114. Mansoori P, Chams C, Davatchi F, Shahram F, Akbarian M, Gharipdoost F, Nadji A, Chams H. Relationship of pathergy phenomenon and Behçet's disease manifestations. In: Wechsler B and Godeau P (Eds.): Behçet's Disease,Proceedings of the 6th International Conference on Behçet's Disease. Amsterdam,Excerpta Medica 1993: 367-9.
115. Azizleri G. Behçet hastaliǧinda deri bulgulari. Aktüel Tip Dergisi 1997;2:94.
116. Dilşen N, Koniçe M, Aral O, Ocal L, Inanç M, Gül A. Comparative study of the skin pathergy test with blunt and sharp needles in Behçet's disease: confirmed specificity but decreased sensitivity with sharp needles. Annals of the Rheumatic Disease 1993;52:823-5. (Pubitemid 23328696)
117. Gül U, Gönül M. Oral and genital pathergy in Behçet's disease. Dermatology 2007;215:80-1. (Pubitemid 46976021)
118. Cakir N, Yazici H, Chamberlain MA, Barnes CG, Yurdakul S, Atasoy S, Akcasu A, Iscimen A. Response to intradermal injection of monosodium urate crystals in Behçet's syndrome. Ann Rheum Dis 1991;50:634-6.
119. Davatchi F, Akbaran M, Shahram F, Jamshidi A, Gharibdoost F, Chams C. Iran Behçet's Disease Dynamic Activity Measure. Abstracts of the XIIth European Congress of Rheumatology. Hung Rheumatol Suppl 1991;32:10-100.
120. Dilsen N, Konice M, Urgancioglu M, Aral O, Ocal L, Abit F, Gungel H, Inanc M, Gul A. The correlation between eye lesions and other features of Behcet's disease. In: Behçet' s disease. Eds. Bang D, Lee ES, Lee S. International conference on Behçet's disease. 9th: Seoul, Korea, 2000:852-4.
121. Diri E, Mat C, Hamuryudan V, Yurdakul S, Hizli N, Yazici H. Papulopustular skin lesions are seen more frequently in patients with Behçet's syndrome who have arthritis: a controlled and masked study. Ann Rheum Dis 2001;60:1074-6.
122. Demiroǧlu H, Barişta I, Dündar S. Ophthalmology. Risk factor assessment and prognosis of eye involvement in Behcet's disease in Turkey 1997;104:701-5.
123. Demiroǧlu H, Barişta I, Dündar S. Assessing the risk of deep vein thrombosis in Behçet's disease Thromb Res 1996;84:297-8.
124. Zouboulis CC, Turnbull JR, Martus P. Univariate and multivariate analyses comparing demographic, genetic, clinical, and serological risk factors for severe Adamantiades-Behçet's disease. Adv Exp Med Biol 2003;528:123-6.
125. Dilsen N. Behçet hastaliǧinda tani, gidiş ve prognoz. Aktüel Tip Dergisi 1997;2:108-11.
126. Krause I, Leibovici L, Guedj D, Molad Y, Uziel Y, Weinberger A. Disease patterns of patients with Behçet's disease demonstrated by factor analysis Clin Exp Rheumatol 1999;17:347-50.
127. Krause I, Rosen Y, Kaplan I, Milo G, Guedj D, Molad Y, Weinberger A. Recurrent aphthous stomatitis in Behçet's disease: clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med 1999;28:193-6. (Pubitemid 29188405)
128. Houman H, Ben Ghorbel I, Braham-Sfaxi A, Khanfir M, Ben Ahmed M, Lamloum M, Miled M. Risk factors of neuro-Behçet. Adv Exp Med Biol 2003;528:143-6.
129. Houman MH, Neffati H, Braham A, Harzallah O, Khanfir M, Miled M, Hamzaoui K. Behçet's disease in Tunisia. Demographic, clinical and genetic aspects in 260 patients. Clin Exp Rheumatol 2007;25:58-64.
130. Houman MH, Ben Ghorbel I, Khiari Ben Salah I, Lamloum M, Ben Ahmed M, Miled M. Deep vein thrombosis in Behçet's disease. Clin Exp Rheumatol 2001;19:48-50.
131. Krause I, Uziel Y, Guedj D, Mukamel M, Harel L, Molad Y, Weinberger A. Childhood Behçet's disease: clinical features and comparison with adult-onset disease. Rheumatology (Oxford). 1999;38:457-62.
132. Benamour S, Moudatir A, Ghafirine W, Kabli HE, Bettal S, Amraoui A. Behçet's disease with late onset. In: Behçet' s disease. Eds. Bang D, Lee ES, Lee S. International conference on Behçet's disease. 9th: Seoul, Korea, 2000:507-10.
133. Lee S, Lee ES, Bang D, Jun JB. Clinical manifestations of late-onset Behçet's disease. In: Behçet' s disease. Eds. Bang D, Lee ES, Lee S. International conference on Behçet's disease. 9th: Seoul, Korea, 2000:946-8.
134. Zouboulis CC, Turnbull JR, Martus P. Univariate and multivariate analyses comparing demographic, genetic, clinical, and serological risk factors for severe Adamantiades-Behçet's disease.Adv Exp Med Biol 2003;528:123-6.
135. Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behçet's disease. Int J Dermatol 2003;42:346-51. (Pubitemid 36681714)
136. Gürler A, Boyvat A, Türsen U. Clinical manifestations of Behçet's disease: an analysis of 2147 patients. Yonsei Med J. 1997;38:423-7.
137. Alpsoy E, Donmez L, Onder M, Gunasti S, Usta A, Karincaoglu Y, Kandi B, Buyukkara S, Keseroglu O, Uzun S, Tursen U, Seyhan M, Akman A. Clinical features and natural course of Behçet's disease in 661 cases: a multicentre study. Br J Dermatol 2007;157:901-6.
138. Yazici H, Tüzün Y, Pazarli H, Yurdakul S, Ozyazgan Y, Ozdoǧan H, Serdaroǧlu S, Ersanli M, Ulkü BY, Müftüoǧlu AU. Influence of age of onset and patient's sex on the prevalence and severity of manifestations of Behçet's syndrome. Ann Rheum Dis 1984;43:783-9.
139. Dilsen N. The implications of nonaphthous beginning of Behçet's disease. Adv Exp Med Biol 2003;528:73-6. (Pubitemid 41582738)
140. Jadaon J, Shushan A, Ezra Y, Sela HY, Ozcan C, Rojansky N. Behçet's disease and pregnancy. Acta Obstet Gynecol Scand 2005;84:939-44.
141. Uzun S, Alpsoy E, Durdu M, Akman A. The clinical course of Behçet's disease in pregnancy: a retrospective analysis and review of the literature J Dermatol 2003;30:499-502.
142. Gül U. Pregnancy and Behçet disease. Arch Dermatol 2000;136:1063-4.
143. Bang D, Chun YS, Haam IB, Lee ES, Lee S. The influence of pregnancy on Behçet's disease. Yonsei Med J 1997;38:437-43.
144. Marsal S, Falgá C, Simeon CP, Vilardell M, Bosch JA. Behçet's disease and pregnancy relationship study. Br J Rheumatol 1997;36:234-8. (Pubitemid 127744998)
145. Wechsler B, Généreau T, Biousse V, Vauthier-Brouzes D, Seebacher J, Dormont D, Godeau P. Pregnancy complicated by cerebral venous thrombosis in Behçet's disease. Am J Obstet Gynecol 1995;173:1627-9.
146. Bang D. Clinical comparison of recurrent aphthous ulcer and Behçet's disease. In: Behçet' s disease. Eds. Bang D, Lee ES, Lee S. International conference on Behçet's disease. 9th: Seoul, Korea, 2000:633-7.
147. Shahram F, Chams C, Davatchi F, Nadji A, Akbarian M, Jamshidi A. Familial study in Behçet's disease, analysis of 1242 patients. In: Behçet' s disease. Eds. Bang D, Lee ES, Lee S. International conference on Behçet's disease. 9th: Seoul, Korea, 2000:605-8.
148. Zouboulis ChC, Kötter I, Djawari D, Krause L, Pleyer U, Stadler R, Kirch W, Wollina U, Kohl PK, Keitel W, Ochsendorf FR, Gollnick HP, Borgmann H, Turnbull JR, Keitzer R, Hölzle E, Proksch E, Söhnchen R, Blech H,
149. Zouboulis ChC, Kötter I, Djawari D, Kirch W, Ochsendorf FR, Keitel W, Stadler R, Wollina U, Proksch E, Söhnchen R, Weber H, Gollnick HP, Hölzle E, Fritz K, Licht TH, Orfanos CE. Epidemiological features of Adamantiades-Behçet's disease in Germany and in Europea. In: Behçet' s disease. Eds. Bang D, Lee ES, Lee S. International conference on Behçet's disease. 9th: Seoul, Korea 2000:576-80.
150. Prokaeva T, Reshetnyak T, Kuzin A, Rabinovich I, Ermakova N, Nassonova V. Evaluation of existing diagnosis criteria for Behçet's disease. In: Behçet' s disease. Eds. Bang D, Lee ES, Lee S. International conference on Behçet's disease. 9th: Seoul, Korea 2000:598-603.
151. Shimizu T, Ehrlich GE, Inaba G, Hayashi K. Behçet disease (Behçet syndrome). Semin Arthritis Rheum 1979;8:223-60.
152. Kötter I, Vonthein R, Gaydin I, Mler C, Kanz L, Zierhut M, Stubiger N. Behçet's disease in patients of German and Turkish Origin- A comparative study. In: Admantiades-Behçet's disease. Ed Zouboulis CC, Kluwer Academic/Plenum Publishers, New York 2003:53-8.
153. Neves FS, Moraes JC, Kowalski SC, Goldenstein-Schainberg C, Lage LV, Gonçalves CR. Cross-cultural adaptation of the Behçet's Disease Current Activity Form (BDCAF) to Brazilian Portuguese language. Clin Rheumatol 2007;26:1263-7.
154. Suzuki KM, Suzuki N. Behcet's disease. Clin Exp Med 2004;4:10-20.
155. Hamuryudan V, Fresko I, Direskeneli H, Tenant MJ, Yurdakul S, Akoglu T, Yazici H. Evaluation of the Turkish translation of a disease activity form for Behçet's syndrome. Rheumatology (Oxford) 1999;38:734-6.
156. Baltaci M. A review on disease activity scores in Behçet's disease. Arthritis Res Ther 2005;5:7.
157. Bodur H, Borman P, Ozdemir Y, Atan C, Kural G. Quality of life and life satisfaction in patients with Behçet's disease: relationship with disease activity. Clin Rheumatol 2006;25:329-33.
158. Lawton G, Bhakta BB, Chamberlain MA, Tennant A. The Behçet's disease activity index. Rheumatology 2004;43:73-8.
159. Monastero R, Camarda C, Pipia C, Lopez G, Camarda LK, Baiamonte V, Ferrante A, Triolo G, Camarda R. Cognitive impairment in Behçet's disease patients without overt neurological involvement. J Neurol Sci 2004;220:99-104. (Pubitemid 38622106)
160. Bhakta B, Hamuryudan V, Brennan P, Chamberlain MA, Barnes CG, Silman AJ. Assessment of disease activity in Behçet's disease. In. Behçet's disease. Eds: Godeau P, Wechsler B. Elsevier Science Publishers B.V. Amsterdam 1993:235-40.
161. Simsek I, Meric C, Erdem H, Pay S, Kilic S, Dinc A. Accuracy of recall of the items included in disease activity forms of Behçet's disease: comparison of retrospective questionnaires with a daily telephone interview. Clin Rheumatol 2008;27:1255-60.
162. Yosipovitch G, Shohat B, Bshara J, Wysenbeek A, Weinberger A. Elevated serum interleukin 1 receptors and interleukin 1B in patients with Behçet's disease: correlations with disease activity and severity. Isr J Med Sci 1995;31:345-8.
163. Krause I, Rosen Y, Kaplan I, Milo G, Guedj D, Molad Y, Weinberger A. Recurrent aphthous stomatitis in Behçet's disease: clinical features and correlation with systemic disease expression and severity. J Oral Pathol Med 1999;28:193-6.
164. Krause I, Mader R, Sulkes J, Paul M, Uziel Y, Molad Y, Weinberger A. The expression of Behçet's disease in Israeli ethnic groups. In: Behçet' s disease. Eds. Bang D, Lee ES, Lee S. International conference on Behçet's disease. 9th: Seoul, Korea, 2000:73-6.
165. Kaklamani VG, Vaipoulos G, Markomichelakis N, Palimeris G, Markaki J, Kaklamanis PH. Correlation of the severity of Adamantiades- Behçet's disease with clinical and demographic parameters. Behçet' s disease. Eds. Bang D, Lee ES, Lee S. International conference on Behçet's disease. 9th: Seoul, Korea 2000:902.
166. Lee ES, Kim HS, Bang D, Yu HG, Chung H, Shin DH, Song YW, Park YB, Lee SK, Shin SK, Kim WH, Choi J, Park BJ, Lee S. Development of clinical activity form for Korean patients with Behçet's disease. Adv Exp Med Biol 2003;528:153-6.
167. Tanriverdi N, Taskintuna, Duru C, Ozdal P, Ortac S, Firat E. Healthrelated quality of life in Behçet patients with ocular involvement. Jpn J Ophthalmol 2003;47:85-92.
168. Blackford S, Finlay AY, Roberts DL. Quality of life in Behçet's syndrome: 335 patients surveyed. Br J Dermatol 1997;136:293. (Pubitemid 27062747)
169. Mumcu G, Niazi S, Stewart J, Hagi-Pavli E, Gokani B, Seoudi N, Ergun T, Yavuz S, Stanford M, Fortune F, Direskeneli H. Oral health and related quality of life status in patients from UK and Turkey: a comparative study in Behcet's disease. J Oral Pathol Med 2009;38:406-9.
170. Davis GL, Brissett D. Experiencing Behçet's disease: A view from 245 patients. In: Behçet's disease. Eds: Godeau P, Wechsler B. Elsevier Science Publishers B.V. Amsterdam 1993:211-4.
171. Prokaeva T, Alekberova Z, Nassonova V. Fatigue in Behçet's disease. Eds. Bang D, Lee ES, Lee S. International conference on Behçet's disease. 9th: Seoul, Korea, 2000:974-81.
172. http://www.behcet.ws/